Neuropsychiatry and Addictions Institute (INAD) of Parc de Salut Mar, Barcelona, Spain.
Department of Psychiatry and Legal Medicine, Autonomous University of Barcelona, Barcelona, Spain.
Schizophr Bull. 2020 Dec 1;46(6):1547-1557. doi: 10.1093/schbul/sbaa038.
Schizophrenia (SCZ) has been associated with serotonergic and endocannabinoid systems dysregulation, but difficulty in obtaining in vivo neurological tissue has limited its exploration. We investigated CB1R-5-HT2AR heteromer expression and functionality via intracellular pERK and cAMP quantification in olfactory neuroepithelium (ON) cells of SCZ patients non-cannabis users (SCZ/nc), and evaluated whether cannabis modulated these parameters in patients using cannabis (SCZ/c). Results were compared vs healthy controls non-cannabis users (HC/nc) and healthy controls cannabis users (HC/c). Further, antipsychotic effects on heteromer signaling were tested in vitro in HC/nc and HC/c. Results indicated that heteromer expression was enhanced in both SCZ groups vs HC/nc. Additionally, pooling all 4 groups together, heteromer expression correlated with worse attentional performance and more neurological soft signs (NSS), indicating that these changes may be useful markers for neurocognitive impairment. Remarkably, the previously reported signaling properties of CB1R-5-HT2AR heteromers in ON cells were absent, specifically in SCZ/nc treated with clozapine. These findings were mimicked in cells from HC/nc exposed to clozapine, suggesting a major role of this antipsychotic in altering the quaternary structure of the CB1R-5-HT2AR heteromer in SCZ/nc patients. In contrast, cells from SCZ/c showed enhanced heteromer functionality similar to HC/c. Our data highlight a molecular marker of the interaction between antipsychotic medication and cannabis use in SCZ with relevance for future studies evaluating its association with specific neuropsychiatric alterations.
精神分裂症 (SCZ) 与血清素能和内源性大麻素系统失调有关,但由于难以获得体内神经组织,其研究受到限制。我们通过对 SCZ 患者非大麻使用者 (SCZ/nc) 的嗅神经上皮 (ON) 细胞中细胞内 pERK 和 cAMP 的定量,研究了 CB1R-5-HT2AR 异源二聚体的表达和功能,并评估了大麻是否会调节使用大麻的患者的这些参数 (SCZ/c)。结果与健康对照非大麻使用者 (HC/nc) 和健康对照大麻使用者 (HC/c) 进行了比较。此外,还在 HC/nc 和 HC/c 中进行了体外抗精神病药物对异源二聚体信号的作用测试。结果表明,与 HC/nc 相比,两组 SCZ 患者的异源二聚体表达均增强。此外,将所有 4 组数据汇总后,异源二聚体表达与注意力表现更差和更多的神经软体征 (NSS) 相关,表明这些变化可能是神经认知障碍的有用标志物。值得注意的是,先前在 ON 细胞中报道的 CB1R-5-HT2AR 异源二聚体的信号特性在接受氯氮平治疗的 SCZ/nc 中不存在。在暴露于氯氮平的 HC/nc 细胞中也出现了这些发现,这表明这种抗精神病药物在改变 SCZ/nc 患者 CB1R-5-HT2AR 异源二聚体的四级结构方面发挥了主要作用。相比之下,来自 SCZ/c 的细胞显示出与 HC/c 相似的增强的异源二聚体功能。我们的数据突出了精神分裂症中抗精神病药物和大麻使用之间相互作用的分子标志物,这对于未来评估其与特定神经精神改变的关联的研究具有重要意义。